Market Overview:
The global respiratory syncytial virus attachment glycoprotein market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of respiratory syncytial virus (RSV) infections, rising demand for prophylactic and therapeutic vaccines, and growing investments by key players in this market. Based on type, the global respiratory syncytial virus attachment glycoprotein market can be segmented into VIS-RSV, TRL-3D3, AX-14, MVA-RSV, and others. VIS-RSV is expected to account for the largest share of the global respiratory syncytial virus attachment glycoprotein market in 2018. This segment is projected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. TRL-3D3 is also expected to witness significant growth during the forecast period owing its ability to induce strong humoral immune responses against RSV infection.
Product Definition:
RSV attachment glycoprotein (RSV-AG) is a protein that helps RSV attach to cells in the respiratory tract. RSV-AG is important for the virus to infect cells and cause illness. There is currently no vaccine or treatment available for RSV infection, so identification of molecules that mediate viral attachment and entry into cells is important for development of therapies.
VIS-RSV:
VIS-RSV is a protein that acts as an accessory molecule in the process of viral infection. It facilitates entry of the virus into host cells and its growth by attaching to receptors on cell membranes. The mechanism by which VIS-RSV accomplishes this is not well understood, but it has been shown to bind preferentially to epithelial cells (the main target cell type) and fibroblasts.
TRL-3D3:
The TRL-3D3 is a synthetic, non-glycosylated form of the human immunoglobulin M (IgM). It is used in the treatment of respiratory syncytial virus (RSV) infection. The drug was developed by chance discovery as an anti-RSV antibody by researchers at Texas Research Laboratories and has been undergoing clinical trials since its inception.
Application Insights:
Based on application, the global respiratory syncytial virus attachment glycoprotein market is segmented into hospital, clinic or healthcare facility and others. Hospital was the largest revenue generating segment in 2017 due to high usage of RAVAs during treatment for SARS-CoV-2. In addition, hospitals are considered as one of the highest risk sites for spread of infection due to close contact between patients and their caregivers. This factor is anticipated to drive demand over the forecast period.
The Clinic or healthcare facility application segment is expected witness lucrative growth over the forecast period owing to increasing awareness about prevention measures against coronavirus infections among individuals with diabetes mellitus and other chronic diseases who have been reported as a high risk group for development of severe complications caused by CoV-2 infection such as pneumonia along with its associated mortality rate which has increased significantly since 2014 globally (3).
Regional Analysis:
North America dominated the global respiratory syncytial virus attachment glycoprotein market in 2017. The high prevalence of RSV, rising number of hospital visits due to the disease, and increasing healthcare expenditure are some factors contributing to its largest share. In addition, favorable reimbursement policies for expensive drugs and a large number of new product launches are also expected to drive growth during the forecast period.
Asia Pacific is expected to be one of the fastest growing regions over the forecast period owing to an increase in awareness about infectious diseases among children as well as adults coupled with rising disposable income especially in China & India.
Growth Factors:
- Increasing incidence of respiratory syncytial virus (RSV) infection
- Rising demand for prophylactic and therapeutic drugs for RSV infection
- Growing awareness about RSV infections and its prevention
- Technological advancements in the development of novel vaccines and therapeutics against RSV
- increasing funding for research on RSV
Scope Of The Report
Report Attributes
Report Details
Report Title
Respiratory Syncytial Virus Attachment Glycoprotein Market Research Report
By Type
VIS-RSV, TRL-3D3, AX-14, MVA-RSV, Others
By Application
Clinic, Hospital, Others
By Companies
Agilvax, Inc., Bavarian Nordic A/S, Emergent BioSolutions Inc., F. Hoffmann-La Roche Ltd., Trellis Bioscience, Inc., Agilvax, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
229
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Respiratory Syncytial Virus Attachment Glycoprotein Market Report Segments:
The global Respiratory Syncytial Virus Attachment Glycoprotein market is segmented on the basis of:
Types
VIS-RSV, TRL-3D3, AX-14, MVA-RSV, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Agilvax, Inc.
- Bavarian Nordic A/S
- Emergent BioSolutions Inc.
- F. Hoffmann-La Roche Ltd.
- Trellis Bioscience, Inc.
- Agilvax, Inc.
Highlights of The Respiratory Syncytial Virus Attachment Glycoprotein Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- VIS-RSV
- TRL-3D3
- AX-14
- MVA-RSV
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Respiratory Syncytial Virus Attachment Glycoprotein Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
The respiratory syncytial virus attachment glycoprotein is a protein that helps the virus attach to cells. The attachment glycoprotein can help the virus enter cells and spread, and it can also cause damage to the cell.
Some of the key players operating in the respiratory syncytial virus attachment glycoprotein market are Agilvax, Inc., Bavarian Nordic A/S, Emergent BioSolutions Inc., F. Hoffmann-La Roche Ltd., Trellis Bioscience, Inc., Agilvax, Inc..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Respiratory Syncytial Virus Attachment Glycoprotein Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Respiratory Syncytial Virus Attachment Glycoprotein Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Respiratory Syncytial Virus Attachment Glycoprotein Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Respiratory Syncytial Virus Attachment Glycoprotein Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Respiratory Syncytial Virus Attachment Glycoprotein Market Size & Forecast, 2020-2028
4.5.1 Respiratory Syncytial Virus Attachment Glycoprotein Market Size and Y-o-Y Growth
4.5.2 Respiratory Syncytial Virus Attachment Glycoprotein Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 VIS-RSV
5.2.2 TRL-3D3
5.2.3 AX-14
5.2.4 MVA-RSV
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Respiratory Syncytial Virus Attachment Glycoprotein Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Respiratory Syncytial Virus Attachment Glycoprotein Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 VIS-RSV
9.6.2 TRL-3D3
9.6.3 AX-14
9.6.4 MVA-RSV
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 VIS-RSV
10.6.2 TRL-3D3
10.6.3 AX-14
10.6.4 MVA-RSV
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 VIS-RSV
11.6.2 TRL-3D3
11.6.3 AX-14
11.6.4 MVA-RSV
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 VIS-RSV
12.6.2 TRL-3D3
12.6.3 AX-14
12.6.4 MVA-RSV
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 VIS-RSV
13.6.2 TRL-3D3
13.6.3 AX-14
13.6.4 MVA-RSV
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Respiratory Syncytial Virus Attachment Glycoprotein Market: Competitive Dashboard
14.2 Global Respiratory Syncytial Virus Attachment Glycoprotein Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Agilvax, Inc.
14.3.2 Bavarian Nordic A/S
14.3.3 Emergent BioSolutions Inc.
14.3.4 F. Hoffmann-La Roche Ltd.
14.3.5 Trellis Bioscience, Inc.
14.3.6 Agilvax, Inc.
